{"id":"W4385989336","doi":"10.1016/j.annonc.2023.08.003","title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Principia Biopharma; ImmunoMedics; Sierra Oncology; Loxo Oncology; Chugai Pharmaceutical; AstraZeneca; Genentech; Amgen; Science Foundation Ireland; Seagen; G1 Therapeutics; Daiichi-Sankyo; MacroGenics; Silverback Therapeutics; FibroGen; Puma Biotechnology; Novartis Pharmaceuticals Corporation; F-star Therapeutics; Aminex Therapeutics; F. Hoffmann-La Roche; Genomic Health; Menarini Silicon Biosystems; BeiGene; University of Wisconsin Carbone Cancer Center; Sun Pharma; Five Prime Therapeutics; Array BioPharma; Merck KGaA; Memorial Sloan-Kettering Cancer Center; National Institutes of Health; Natera; BioMarin Pharmaceutical; Astellas Pharma; Eisai; Daiichi Sankyo Europe; University of Wisconsin-Madison; National Breast Cancer Foundation; Incyte; Servier; Gilead Sciences; Exelixis; Jounce Therapeutics; Breast Cancer Research Foundation; Apollomics; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer","keywords":"Fulvestrant; Neratinib; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Cancer; Gastroenterology; Progressive disease; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005853532,0.0003044948,0.001334029,0.000234465,0.0001514422,0.00002050874,0.0001773839,0.0001173522,0.0002339137],"category_scores_gemma":[0.0002116442,0.0001980235,0.0004349027,0.0009174792,0.0004814866,0.0001143905,0.0000534442,0.0001777164,0.000005100664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007405975,"about_ca_system_score_gemma":0.0003585987,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002331216,"about_ca_topic_score_gemma":0.002845718,"domain_scores_codex":[0.9977917,0.0002876837,0.0006719864,0.0004858026,0.0002973751,0.0004654298],"domain_scores_gemma":[0.9961937,0.00257448,0.0003888832,0.0003511108,0.0003394939,0.0001523041],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1384409,0.001649009,0.06043781,0.0001858934,0.03691323,0.0002003217,0.006295879,0.0003840712,0.009955742,0.0005093502,0.004186667,0.7408412],"study_design_scores_gemma":[0.06414041,0.004391784,0.9039834,0.0001278196,0.005005617,0.00003570381,0.003399866,0.001330159,0.004241595,0.003174548,0.009728864,0.0004402552],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9460942,0.0006872932,0.000755734,0.04737687,0.0002822809,0.00149414,0.003137969,0.00006430534,0.0001072048],"genre_scores_gemma":[0.994646,0.0006848124,0.00138356,0.002228401,0.0002000081,0.0004337229,0.000184552,0.00004191795,0.0001970233],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8435456,"threshold_uncertainty_score":0.8075165,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09886301706774538,"score_gpt":0.4203931923658902,"score_spread":0.3215301752981448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}